Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: A systematic literature review highlighting differences from the idiopathic forms
Autoimmunity Reviews,
Год журнала:
2024,
Номер
23(7-8), С. 103589 - 103589
Опубликована: Июль 1, 2024
Язык: Английский
PET-CT in Polymyalgia Rheumatica: When and for what—A Critical Review
Опубликована: Июнь 20, 2024
Polymyalgia
rheumatica
(PMR)
is
an
inflammatory
disease
common
in
people
aged
50
years
and
older.
This
condition
characterized
by
the
presence
of
pain
stiffness
involving
mainly
shoulder
pelvic
girdle.
Besides
frequent
association
with
giant
cell
arteritis
(GCA),
several
conditions
may
mimic
PMR
or
present
features.
Since
diagnosis
basically
clinical,
adequate
this
usually
required.
Positron
emission
tomography-computed
tomography
(PET-CT)
has
proved
to
be
a
useful
tool
for
PMR.
The
use
18F-FDG-PET
imaging
appears
promising
as
it
provides
detailed
information
on
activity
that
not
evident
traditional
methods.
However,
since
PET-CT
strictly
necessary
PMR,
clinicians
should
consider
situations
which
technique
can
used
patients
suspected
Язык: Английский
Polymyalgia Rheumatica (PMR) and Polymyalgia Rheumatica-like (PMR-like) Manifestations in Cancer Patients Following Treatment with Nivolumab and Pembrolizumab: Methodological Blurred Points Identified Through a Systematic Review of Published Case Reports
Medical Sciences,
Год журнала:
2025,
Номер
13(2), С. 34 - 34
Опубликована: Апрель 1, 2025
Background:
Among
rheumatologic
diseases
following
therapy
with
immune
checkpoint
inhibitors
(ICIs),
the
cases
of
cancer
patients
diagnosed
as
having
polymyalgia
rheumatica
(PMR),
particularly
nivolumab
and
pembrolizumab,
has
been
steadily
rising
in
published
reports.
Objectives:
We
performed
a
systematic
review
case
reports
aim
answering
these
questions:
(1)
Is
PMR
pembrolizumab
an
adverse
drug
reaction
(ADR)?
(2)
there
difference
between
those
pembrolizumab?
Methods:
Based
on
Preferred
Reporting
Items
for
Systematic
Reviews
Meta-Analysis
(PRISMA)
guidelines,
comprehensive
literature
search
three
main
bibliographic
databases:
MEDLINE
(Ovid
interface),
EMBASE,
COCHRANE
Library
was
carried
out
27
December
2024.
This
no
registration
number.
Results:
Data
were
extracted
from
12
patients.
Namely,
5
followed
treatment
7
pembrolizumab.
Validated
scales
ADR
assessment—such
Naranjo’s
scale—were
not
used
10
Additionally,
validated
diagnostic
or
classification
criteria
majority
related
to
nivolumab.
On
contrary,
clinical
judgment
alone
rule
almost
all
Finally,
time
interval
manifestations
nivolumab/pembrolizumab
ranged
one
14
cycles
(fully
compatible
pharmacokinetics).
Conclusions:
Our
highlighted
significant
methodological
blurred
lines
categorization
Язык: Английский
Are There Definite Disease Subsets in Polymyalgia Rheumatica? Suggestions from a Narrative Review
Healthcare,
Год журнала:
2025,
Номер
13(11), С. 1226 - 1226
Опубликована: Май 23, 2025
Background:
Polymyalgia
rheumatica
(PMR)
has
a
multifaceted
onset
and
course,
making
distinction
between
true
PMR
so-called
“polymyalgic
syndrome”
(that
is,
similar
manifestations
caused
by
different
conditions)
is
far
from
easy
in
clinical
practice.
The
existence
of
subsets
within
may
further
complicate
the
diagnostic
question.
Distinguishing
PMR-mimicking
conditions
does
not
just
carry
nomenclature
value
speculative
significance.
Indeed,
correct
diagnosis
influences
treatment,
prognosis,
epidemiological
assessments,
health
policies.
Objectives:
We
aimed
to
(1)
ascertain
presence
definite
peculiar
subset/subgroup/cluster
scientific
literature;
(2)
describe
any
possible
subset/cluster/subgroup
identified
at
least
two
studies.
Methods:
performed
non-systematic
(PRISMA
protocol
followed)
literature
search
on
Embase
Medline
(OVID
interface).
following
terms
were
used:
polymyalgia
rheumatica,
subset,
cluster,
subgroup,
subclinical
giant
cell
arteritis,
mimicking
conditions,
rheumatica-like
immunotherapy,
checkpoint
inhibitor,
acute-phase
reactants
or
proteins,
vaccination,
infection,
calcium
pyrophosphate
deposition
disease
chondrocalcinosis.
Each
paper’s
reference
list
was
scanned
for
additional
publications
meeting
this
study’s
aim.
Abstracts
submitted
conferences
non-peer-reviewed
sources
included.
Results:
initial
yielded
2492
papers,
which
2389
articles
excluded
based
title
abstract
screening.
A
total
103
underwent
full-length
review,
84
them
finally
assessed
eligibility.
seven
large
could
be
identified:
with
normal
reactants;
an
infection
trigger;
(3)
vaccination
(4)
arteritis
(GCA);
(5)
(CPPD);
(6)
immune
inhibitor
(ICI)
therapy;
(7)
clusters
(based
statistic
clustering
methods).
Conclusions:
baseline
trigger
categorized
as
disease.
GCA
most
cases
PMR/CPPD
should
mimickers.
Finally,
studies
are
required
better
categorize
some
emerging
cluster
analyses,
ICI-induced
PMR.
Язык: Английский
Positron Emission Tomography/Computed Tomography in Polymyalgia Rheumatica: When and for What—A Critical Review
Diagnostics,
Год журнала:
2024,
Номер
14(14), С. 1539 - 1539
Опубликована: Июль 17, 2024
Polymyalgia
rheumatica
(PMR)
is
an
inflammatory
disease
common
in
people
aged
50
years
and
older.
This
condition
characterized
by
the
presence
of
pain
stiffness
involving
mainly
shoulder
pelvic
girdle.
Besides
frequent
association
with
giant
cell
arteritis
(GCA),
several
conditions
may
mimic
PMR
or
present
features.
Since
diagnosis
basically
clinical,
adequate
this
usually
required.
Positron
emission
tomography/computed
tomography
(PET-CT)
has
proved
to
be
a
useful
tool
for
PMR.
The
use
18F-FDG-PET
imaging
appears
promising
as
it
provides
detailed
information
on
activity
that
not
evident
traditional
methods.
However,
since
PET-CT
strictly
necessary
PMR,
clinicians
should
consider
situations
which
technique
can
used
patients
suspected
Язык: Английский